In a placebo-controlled double-blind cross-over study, short-term administration of dapagliflozin (10 mg for 3 days) did not improve whole-body sensitivity of glucose disposal to insulin during euglycemic-hyperinsulinemia (371). Here, INS is linked to hyperinsulinism.